These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32529802)

  • 1. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
    Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
    J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
    Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
    IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
    Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
    Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TUG1 promotes the development of prostate cancer by regulating RLIM.
    Guo BH; Zhao Q; Li HY
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
    Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
    Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
    Abramovic I; Pezelj I; Dumbovic L; Skara Abramovic L; Vodopic T; Bulimbasic S; Stimac G; Bulic-Jakus F; Kulis T; Katusic Bojanac A; Tomas D; Ulamec M; Sincic N
    Prostate; 2024 Sep; 84(12):1128-1137. PubMed ID: 38824441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
    Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
    Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
    Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
    Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer antigen 3 gene expression in peripheral blood and urine sediments from prostate cancer and benign prostatic hyperplasia patients versus healthy individuals.
    Moradi Sardareh H; Goodarzi MT; Yadegar-Azari R; Poorolajal J; Mousavi-Bahar SH; Saidijam M
    Urol J; 2014 Nov; 11(6):1952-8. PubMed ID: 25433473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
    Dülgeroğlu Y; Eroğlu O
    Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
    DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer.
    Fawzy MS; Mohamed RH; Elfayoumi AR
    Med Oncol; 2015 Mar; 32(3):74. PubMed ID: 25698533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level.
    Xue D; Zhou CX; Shi YB; Lu H; He XZ
    Tumour Biol; 2015 May; 36(5):3541-7. PubMed ID: 25557788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.